Research Papers:

This article has been retracted. Retraction in: Oncotarget. 2022; 13:1322-1322.

Colon cancer-induced interleukin-35 inhibits beta-catenin-mediated pro-oncogenic activity

Yueqiang Jiang, Yanling Ma, RuiChao Li _ and JianHai Sun

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:11989-11998. https://doi.org/10.18632/oncotarget.22857

Metrics: PDF 1924 views  |   HTML 2781 views  |   ?  


Yueqiang Jiang1,*, Yanling Ma2,*, RuiChao Li1 and JianHai Sun2

1Department of Gerontology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China

2Department of Oncology, the Third People’s Hospital, Wuhan, Hubei Province, China

*Co-first author

Correspondence to:

RuiChao Li, email: [email protected]

JianHai Sun, email: [email protected]

Keywords: colon cancer; IL-35; β-catenin; inhibition; metastasis

Received: May 23, 2017    Accepted: November 11, 2017    Published: December 01, 2017


The occurrence and development of colon cancer is closely related to inflammation. Therefore, this study was conducted a current retrospective research to study the effect of IL-35 (interleukin 35), a newly identified anti-infective factor, on colon cancer development. The expression of IL-35 in colon cancer samples and their adjacent normal mucosa by real-time PCR, ELISA (enzyme-linked immunosorbent assay). The effect of IL-35 on patient survival, colon cancer progression, and its effect on Wnt/β-catenine signaling pathway was also assessed. IL-35 is minimally expressed in colon cancer tissues but is highly expressed in adjacent normal tissues. The down-regulation of IL-35 was significantly associated with the American Cancer Joint Committee stage and overall survival of colon cancer patients. The overexpression of IL-35 in colon cancer cells inhibits cell migration, invasion, proliferation, colony formation and cancer stem cells by inhibiting beta-catenin. IL-35 inhibits colon neoplasms in mouse. Our results suggest that IL-35 has an inhibitory effect on the development of colon cancer as a novel prognostic indicator and potential therapeutic target.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22857